JP7109377B2 - 光経皮酸素モニタリングのシステム及び方法 - Google Patents
光経皮酸素モニタリングのシステム及び方法 Download PDFInfo
- Publication number
- JP7109377B2 JP7109377B2 JP2018559727A JP2018559727A JP7109377B2 JP 7109377 B2 JP7109377 B2 JP 7109377B2 JP 2018559727 A JP2018559727 A JP 2018559727A JP 2018559727 A JP2018559727 A JP 2018559727A JP 7109377 B2 JP7109377 B2 JP 7109377B2
- Authority
- JP
- Japan
- Prior art keywords
- oxygen
- oxygenation
- oxygenation monitor
- monitor
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims description 138
- 239000001301 oxygen Substances 0.000 title claims description 138
- 229910052760 oxygen Inorganic materials 0.000 title claims description 138
- 230000003287 optical effect Effects 0.000 title claims description 72
- 238000012544 monitoring process Methods 0.000 title claims description 24
- 238000000034 method Methods 0.000 title description 14
- 239000000523 sample Substances 0.000 claims description 109
- 238000006213 oxygenation reaction Methods 0.000 claims description 83
- 150000004032 porphyrins Chemical class 0.000 claims description 38
- 238000005259 measurement Methods 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 14
- 229920000642 polymer Polymers 0.000 claims description 10
- 238000004891 communication Methods 0.000 claims description 9
- 230000001419 dependent effect Effects 0.000 claims description 9
- 239000013307 optical fiber Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 239000004065 semiconductor Substances 0.000 claims description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 5
- 229910001882 dioxygen Inorganic materials 0.000 claims description 5
- 238000002496 oximetry Methods 0.000 claims description 4
- 229910044991 metal oxide Inorganic materials 0.000 claims description 3
- 150000004706 metal oxides Chemical class 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 description 15
- 206010052428 Wound Diseases 0.000 description 14
- 230000008901 benefit Effects 0.000 description 13
- 239000000975 dye Substances 0.000 description 13
- 230000010412 perfusion Effects 0.000 description 12
- 230000000287 tissue oxygenation Effects 0.000 description 12
- 238000004020 luminiscence type Methods 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 238000002266 amputation Methods 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 6
- 125000001425 triazolyl group Chemical group 0.000 description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000002583 angiography Methods 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000002639 hyperbaric oxygen therapy Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000004497 NIR spectroscopy Methods 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000000412 dendrimer Substances 0.000 description 3
- 229920000736 dendritic polymer Polymers 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- BIAZEQPYCCADLD-YFKPBYRVSA-N (2s)-2-(ethylamino)pentanedioic acid Chemical group CCN[C@H](C(O)=O)CCC(O)=O BIAZEQPYCCADLD-YFKPBYRVSA-N 0.000 description 2
- 101100366935 Caenorhabditis elegans sto-2 gene Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000034972 Sudden Infant Death Diseases 0.000 description 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 1
- FHNFHKCVQCLJFQ-NJFSPNSNSA-N Xenon-133 Chemical compound [133Xe] FHNFHKCVQCLJFQ-NJFSPNSNSA-N 0.000 description 1
- NPRDEIDCAUHOJU-UHFFFAOYSA-N [Pt].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 Chemical class [Pt].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 NPRDEIDCAUHOJU-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010252 digital analysis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000010393 epithelial cell migration Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000001782 photodegradation Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- -1 polydimethylsiloxane Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 229940106670 xenon-133 Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
- A61B5/14552—Details of sensors specially adapted therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/04—Arrangements of multiple sensors of the same type
- A61B2562/046—Arrangements of multiple sensors of the same type in a matrix array
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/205—Blood composition characteristics partial oxygen pressure (P-O2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Optics & Photonics (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Diabetes (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Description
本出願は、2016年5月13日に出願された米国特許出願第62/335,961号の優先権を主張する。
適用しない。
うな検体の存在によって光吸収特性(吸収波長又は吸収断面など)を調節することができる染料などの分子を利用することもできる。
現在のスタンダード・オブ・ケアViOptixデバイスに対するポリマベースの酸素感知ペイント・オン製剤のバリデーション研究が行われた。乳房切除術及び乳房再建術後48時間、移植された組織フラップをモニタした臨床研究で検証を行った。
Claims (47)
- 光ルミネセンス酸素感知プローブと、
前記プローブに光子を向けるように構成された光子源と、
前記光子源が前記光子を前記プローブに向けたときに前記プローブから発光される光を検出するように構成された光検出器と、
前記光子源及び前記光検出器と電気通信し、前記光検出器から受信した電気信号から前記プローブに隣接する酸素のレベルを計算するようにその内部に記憶されたプログラムを実行するように構成されたコントローラと、
酸素不透過性膜を介して前記光ルミネセンス酸素感知プローブの表面に取り付けられる回路基板を備える支持構造体と、を備え、
前記光子源、前記光検出器、及び前記コントローラは、前記支持構造内又は上に配置されている
酸素化モニタ。 - 前記光ルミネセンス酸素感知プローブがポルフィリンを含んでいる、請求項1に記載の酸素化モニタ。
- 前記光ルミネセンス酸素感知プローブは、ポルフィリンが含浸されたポリマ材料を含む、請求項1に記載の酸素化モニタ。
- 前記光ルミネセンス酸素感知プローブは、燐光性メソ非置換ポルフィリンが含浸されたポリマを含む、請求項1に記載の酸素化モニタ。
- 前記光ルミネセンス酸素感知プローブは、正確なpO2測定のための参照標準として働く緑色発光色素を含む、請求項1に記載の酸素化モニタ。
- 前記光ルミネセンス酸素感知プローブは、光子源からの青色光によって励起されると赤色燐光を発光する、請求項1に記載の酸素化モニタ。
- 前記光子源は青色発光ダイオードを含む、請求項1に記載の酸素化モニタ。
- 前記光子源はオレンジ色の発光ダイオードを含む、請求項1に記載の酸素化モニタ。
- 前記光検出器は、1つ又は複数の赤色感度フォトダイオード検出器を含む、請求項1に記載の酸素化モニタ。
- 前記光検出器は、1つ又は複数の赤色感知光電子増倍管を含む、請求項1に記載の酸素化モニタ。
- 前記光検出器は、1つ又は複数の赤色感知アバランシェフォトダイオード検出器を含む、請求項1に記載の酸素化モニタ。
- 前記光検出器は、1つ又は複数の赤色感知電荷結合素子(CCD)を含む、請求項1に記載の酸素化モニタ。
- 前記光検出器は、1つ又は複数の赤色感知相補型金属酸化物半導体(CMOS)デバイスを含む、請求項1に記載の酸素化モニタ。
- 前記光検出器は、1つ又は複数の緑色感知フォトダイオード検出器を含む、請求項5に記載の酸素化モニタ。
- 前記光検出器は、1つ又は複数の緑色感知光電子増倍管を含む、請求項5に記載の酸素化モニタ。
- 前記光検出器は、1つ又は複数の緑色感知アバランシェフォトダイオード検出器を含む、請求項5に記載の酸素化モニタ。
- 前記光検出器は、1つ又は複数の緑色感知電荷結合素子(CCD)を含む、請求項5に記載の酸素化モニタ。
- 前記光検出器は、1つ又は複数の緑色感知相補型金属酸化膜半導体(CMOS)デバイスを含む、請求項5に記載の酸素化モニタ。
- 前記回路基板はフレキシブルである、請求項1に記載の酸素化モニタ。
- 前記光検出器によって検出される燐光強度は、患者の組織のpO2に反比例する、請求項1に記載の酸素化モニタ。
- 燐光寿命における酸素依存性変化が前記1つ又は複数の光検出器によって捕捉され、燐光寿命における前記酸素依存性変化が分析されて、患者の組織の経皮酸素測定が提供される、請求項1に記載の酸素化モニタ。
- 赤色発光燐光強度の酸素依存性変化が、前記光検出器の1つ又は複数の赤色感度フォトダイオード検出器によって捕捉され、前記赤色発光燐光強度の酸素依存性変化が、前記光検出器の1つ又は複数の緑色感度フォトダイオード検出器で補捉された緑色発光に対して参照され、前記コントローラの回路が用いられて患者の組織の経皮酸素測定値が提供される、請求項1に記載の酸素化モニタ。
- 前記コントローラは、その内部に記憶されたプログラムを実行して、スターン・ヴォルマ関係を用いて患者の組織の事前較正された経皮的酸素張力測定値を提供するように構成される、請求項1に記載の酸素化モニタ。
- 前記プローブに隣接する酸素のレベルは、1つ又は複数のフルオロフォアプローブ及び1つ又は複数の燐光プローブを利用することによって報告され、
前記1つ又は複数のフルオロフォアプローブの1つ又は複数の発光特性は酸素に対して非感応であり、前記1つ又は複数の燐光プローブの発光特性が分子酸素濃度の影響を受ける、請求項1に記載の酸素化モニタ。 - 前記酸素化モニタは光学的経皮酸素化モニタである、請求項1に記載の酸素化モニタ。
- 前記光ルミネセンス酸素感知プローブは、前記支持構造体に取り外し可能に取り付けられる、請求項1に記載の酸素化モニタ。
- 前記コントローラと電気通信するディスプレイをさらに備え、
前記コントローラは、その内部に記憶された前記プログラムを実行して、前記ディスプレイ上に前記酸素のレベルを表示するように構成される、請求項1に記載の酸素化モニタ。 - 前記コントローラは、その内部に記憶されたプログラムを実行して、ある期間に亘って複数の時刻における前記酸素のレベルの値を記憶するように構成される、請求項1に記載の酸素化モニタ。
- 前記コントローラと電気通信するディスプレイをさらに備え、
前記コントローラは、その内部に記憶された前記プログラムを実行して、ある期間に亘って複数の時刻の前記酸素のレベルの値を表示するように構成されている、請求項1に記載の酸素化モニタ。 - 前記酸素化モニタは患者の身体部分に埋め込み可能である、請求項1に記載の酸素化モニタ。
- 前記光子源から光子を前記プローブに向ける光ガイドをさらに備える、請求項1に記載の酸素化モニタ。
- 前記光ガイドは光ファイバである、請求項31に記載の酸素化モニタ。
- 前記プローブから発光された光を前記光検出器に向ける光ガイドをさらに備える、請求項1に記載の酸素化モニタ。
- 前記光ガイドは光ファイバである、請求項33に記載の酸素化モニタ。
- 前記光ルミネセンス酸素感知プローブは、赤色発光酸素感知製剤と緑色発光基準色素との両方を含むことができ、前記赤色発光酸素感知製剤と前記緑色発光基準色素の両方が光子源からの青色光によって同時に励起される、請求項1に記載の酸素化モニタ。
- 前記支持構造体は、不透過性膜として機能する酸素不透過性材料によって作られる、請求項1に記載の酸素化モニタ。
- 前記光ルミネセンス酸素感知プローブは前記支持構造と接触している、請求項1に記載の酸素化モニタ。
- 前記酸素化モニタは、前記支持構造体を患者の身体の部分に固定するように構成されたバンドを含む、請求項1に記載の酸素化モニタ。
- 酸素化をモニタリングするためのキットであって、
請求項1に記載の酸素化モニタと、
1つ又は複数の光ルミネセンス酸素感知プローブと、を備え、
各光ルミネセンス酸素感知プローブは、前記支持構造体に取り外し可能に取り付けられるように構成されている
酸素化をモニタリングするためのキット。 - 前記酸素化モニタは、前記支持構造体を患者の身体部分に固定するように構成されたバンドを含む、請求項39に記載のキット。
- 各光ルミネセンス酸素感知プローブは、ポルフィリンが含浸されたポリマ材料を含む、請求項39に記載のキット。
- 各光ルミネセンス酸素感知プローブは、燐光性メソ非置換ポルフィリンが含浸されたポリマを含む、請求項39に記載のキット。
- 各光ルミネセンス酸素感知プローブは、プローブによって光の発光を引き起こす波長の光子を透過しないパッケージ内に設けられる、請求項39に記載のキット
- 前記パッケージには、前記光ルミネセンス酸素感知プローブの有効寿命のインジケータが含まれている、請求項43に記載のキット。
- 医療器具と、
前記医療器具に取り付けられている請求項1に記載の酸素化モニタと、を備えたデバイス。 - 前記医療器具はカテーテルとされる、請求項45に記載のデバイス。
- 前記酸素化モニタの前記コントローラと電気的に連絡するディスプレイをさらに備え、
前記コントローラは、その内部に記憶された前記プログラムを実行して、前記ディスプレイ上の前記酸素のレベルを表示するように構成される、請求項46に記載のデバイス。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662335961P | 2016-05-13 | 2016-05-13 | |
US62/335,961 | 2016-05-13 | ||
PCT/US2017/032650 WO2017197385A1 (en) | 2016-05-13 | 2017-05-15 | Systems and methods of optical transcutaneous oxygenation monitoring |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019520114A JP2019520114A (ja) | 2019-07-18 |
JP7109377B2 true JP7109377B2 (ja) | 2022-07-29 |
Family
ID=60267571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018559727A Active JP7109377B2 (ja) | 2016-05-13 | 2017-05-15 | 光経皮酸素モニタリングのシステム及び方法 |
Country Status (4)
Country | Link |
---|---|
US (2) | US11406297B2 (ja) |
EP (1) | EP3454746B1 (ja) |
JP (1) | JP7109377B2 (ja) |
WO (1) | WO2017197385A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102625129B1 (ko) * | 2018-08-23 | 2024-01-15 | 엘지디스플레이 주식회사 | 웨어러블 광 발광 센서 및 이를 구비한 원격 센싱장치 |
US11849923B2 (en) | 2019-10-10 | 2023-12-26 | Worcester Polytechnic Institute | Wearable blood gas monitor |
CN116390686A (zh) * | 2020-09-01 | 2023-07-04 | 通用医疗公司 | 用于监测针对患者的分析物或参数的系统和方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150182166A1 (en) | 2012-07-10 | 2015-07-02 | Conor L. Evans | System and method for monitoring and treating a surface of a subject |
US20150190080A1 (en) | 2014-01-03 | 2015-07-09 | Regents Of The University Of Minnesota | Needle-mounted linear-array oxygen sensor |
WO2015163957A2 (en) | 2014-01-31 | 2015-10-29 | The General Hospital Corporation | System and method for photoluminescence detection |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4041932A (en) * | 1975-02-06 | 1977-08-16 | Fostick Moshe A | Method for monitoring blood gas tension and pH from outside the body |
US5030420A (en) | 1982-12-23 | 1991-07-09 | University Of Virginia Alumni Patents Foundation | Apparatus for oxygen determination |
US5151869A (en) | 1990-02-16 | 1992-09-29 | The Boc Group, Inc. | Frequency domain fluorometry using coherent sampling |
US5315993A (en) | 1990-02-16 | 1994-05-31 | The Boc Group, Inc. | Luminescence monitoring with modulation frequency multiplexing |
US5127405A (en) * | 1990-02-16 | 1992-07-07 | The Boc Group, Inc. | Biomedical fiber optic probe with frequency domain signal processing |
US5593899A (en) | 1993-02-25 | 1997-01-14 | Trustees Of The University Of Pennsylvania | Device and method for measuring tissue oxygenation through the skin using oxygen dependent quenching of phosphorescence |
US5628310A (en) * | 1995-05-19 | 1997-05-13 | Joseph R. Lakowicz | Method and apparatus to perform trans-cutaneous analyte monitoring |
US20060241364A1 (en) * | 2004-10-01 | 2006-10-26 | Academisch Medisch Centrum Of The University Van Amsterdam | System and method for imaging the reflectance of a substrate |
US20070172392A1 (en) * | 2005-12-13 | 2007-07-26 | Sen Chandan K | Apparatus, system and method for tissue oximetry |
US20110105869A1 (en) | 2006-01-04 | 2011-05-05 | The Trustees Of The University Of Pennsylvania | Sensor for Internal Monitoring of Tissue O2 and/or pH/CO2 In Vivo |
WO2010044465A1 (ja) * | 2008-10-17 | 2010-04-22 | 国立大学法人 群馬大学 | 新規化合物およびそれを含む機能性発光プローブ |
US8452366B2 (en) * | 2009-03-16 | 2013-05-28 | Covidien Lp | Medical monitoring device with flexible circuitry |
JP6470748B2 (ja) | 2013-07-10 | 2019-02-13 | ザ ジェネラル ホスピタル コーポレイション | 対象の表面をモニターし、処置するための化合物、システムおよび方法 |
US9789206B2 (en) | 2013-07-10 | 2017-10-17 | The General Hospital Corporation | Compounds, systems, and methods for monitoring and treating a surface of a subject |
US20150217056A1 (en) | 2013-12-31 | 2015-08-06 | Stratos Group Llc | Therapy systems and methods utilizing tissue oxygenation detection |
-
2017
- 2017-05-15 US US16/300,009 patent/US11406297B2/en active Active
- 2017-05-15 EP EP17797019.1A patent/EP3454746B1/en active Active
- 2017-05-15 WO PCT/US2017/032650 patent/WO2017197385A1/en unknown
- 2017-05-15 JP JP2018559727A patent/JP7109377B2/ja active Active
-
2022
- 2022-08-05 US US17/817,687 patent/US20230113642A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150182166A1 (en) | 2012-07-10 | 2015-07-02 | Conor L. Evans | System and method for monitoring and treating a surface of a subject |
JP2015530888A (ja) | 2012-07-10 | 2015-10-29 | ザ ジェネラル ホスピタル コーポレイション | 対象のモニタリングと表面処理のためのシステムおよび方法 |
US20150190080A1 (en) | 2014-01-03 | 2015-07-09 | Regents Of The University Of Minnesota | Needle-mounted linear-array oxygen sensor |
WO2015163957A2 (en) | 2014-01-31 | 2015-10-29 | The General Hospital Corporation | System and method for photoluminescence detection |
Also Published As
Publication number | Publication date |
---|---|
JP2019520114A (ja) | 2019-07-18 |
US11406297B2 (en) | 2022-08-09 |
US20190150811A1 (en) | 2019-05-23 |
EP3454746A1 (en) | 2019-03-20 |
WO2017197385A1 (en) | 2017-11-16 |
US20230113642A1 (en) | 2023-04-13 |
EP3454746A4 (en) | 2020-01-01 |
EP3454746B1 (en) | 2024-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12059481B2 (en) | Compounds, systems, and methods for monitoring and treating a surface of a subject | |
US12059254B2 (en) | Method and device for correcting optical signals | |
US20230113642A1 (en) | Systems and Methods of Optical Transcutaneous Oxygenation Monitoring | |
Marks et al. | A paintable phosphorescent bandage for postoperative tissue oxygen assessment in DIEP flap reconstruction | |
JP2017523863A (ja) | 連続検体センサー | |
JP2023052551A (ja) | 糖尿病管理モニタで分析物濃度を動的に較正および測定するためのシステムおよび方法 | |
WO2022051423A1 (en) | Systems and methods for monitoring an analyte or parameter for a patient | |
US9789206B2 (en) | Compounds, systems, and methods for monitoring and treating a surface of a subject | |
EP3019854B1 (en) | Compounds, systems, and methods for monitoring and treating a surface of a subject | |
US20240358860A1 (en) | Compounds, systems, and methods for monitoring and treating a surface of a subject | |
US20220287597A1 (en) | Detecting and correcting for interference in an analyte monitoring system | |
JP2024519422A (ja) | 分析物監視システムにおける干渉の検出および相関付け | |
JP2024536902A (ja) | 経皮ガス計測装置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200428 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210325 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210427 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210726 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210924 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220111 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220307 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220705 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220719 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7109377 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |